Notice of First Quarter 2023 Results
Financial updatesPharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.
Pharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.
Pharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.
Pharming Group N.V. announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States.
Pharming Group N.V. announces that the Company’s 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST.
Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2022 (the “Period”).
Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.
Pharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.
Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended December 31, 2022. Download the press release below.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.